Friday, November 20, 2026

Pacific Biosciences Of California Stock Plummets 33% In Recent Weeks

Automated market report from our archive (2020-2024), published before source-traceability. How we work

Pacific Biosciences Of California Stock Plummets 33% In Recent Weeks
(VIANEWS) - Pacific Biosciences of California (NASDAQ: PACB) shares have dropped 33.93% in 21 sessions, from EUR5.57 to EUR3.68, as of 09:41 EST Monday morning. This decline follows on the heels of an downward trend observed the prior session that marked the end of a five-day winning streak for NASDAQ - currently up 0.168% at EUR16,428.82; Pacific Biosciences' last closing price was EUR3.68, representing a decrease of 74.71% since their 52-week high price of EUR14.55 was last closing price on Friday.

About Pacific Biosciences of California

Pacific Biosciences of California, Inc. is a premier provider of advanced sequencing solutions designed to resolve genetically complex issues. Their innovative products include sequencing systems, consumable products and reagent kits - plus more! Its proprietary SMRT technology facilitates long-read sequencing and the transformation of DNA samples into double-stranded library formats compatible with its technology. Company offers binding and sequencing kits as well as revio system + sequel systems for real-time monitoring and analysis of single molecule biochemical reactions. Pacific Biosciences serves a range of customers, such as academic and governmental research institutions, genome centers, pharmaceutical companies and agricultural businesses. Pacific Biosciences' products are distributed worldwide through its sales force and distribution partners, while Pacific has also formed strategic alliances with Invitae Corporation and Radboud University Medical to investigate genetic causes of rare and genetic diseases. Established in 2000, its headquarters can be found in Menlo Park, California.

Yearly Analysis

Pacific Biosciences of California's stock is currently trading below its 52-week low of EUR4.00, signalling a potential downward trend. However, sales growth projections estimate 19.2% this year and 46% growth next year. Pacific Biosciences of California currently boasts an EBITDA figure of 7.44, suggesting it is making profits through operations. Unfortunately, without further details regarding financial health and management effectiveness it can be challenging to gauge Pacific Biosciences of California stock's long-term potential growth potential. Overall, investors should proceed with caution when considering an investment in Pacific Biosciences of California stock and conduct additional research to gain a comprehensive understanding of its finances and growth prospects.

Technical Analysis

Pacific Biosciences of California (PACB) has experienced an unprecedented decline in stock price, falling far below both its 50-day and 200-day moving averages (EUR6.68 and EUR9.45, respectively). This decrease has been reflected in trading volume; currently standing at 285,120; 50.77% lower than its previous average volume of 8,639,100. Pacific Biosciences of California stock has displayed an unpredictable pattern of volatility. Over the last week, its intraday variation has averaged 0.088% while month and quarter average volatility rates reached negative 1.40% and positive 4.72%, respectively. Average volatility reached its highest amplitude during those time frames with peak average variance being at 2.66% for last week and month and quarter respectively. Technically speaking, Pacific Biosciences of California stock has been identified by its stochastic oscillator as being overbought (>=80). Investors may wish to proceed with caution and closely track its performance before making any investment decisions.

Quarter Analysis

Pacific Biosciences of California reported an impressive 46.2% sales growth for the current quarter and estimates growth estimates of 25% and 7.1% for both quarters respectively. Revenue growth year-on-year had seen an increase of 113.33% with twelve trailing months showing 200.52M revenue. These results demonstrate how Pacific Biosciences is expanding and performing well within their market niche. More news about Pacific Biosciences of California (PACB).

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

Spotted an error? Use “Correct this article” (bottom right), or select any sentence, to report it or respond to that point.

  1. Published before we listed source documents with each article.
  2. Published 25 Mar 2024
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

Pacific Biosciences Of California Stock Plummets 33% In Recent Weeks | Via.News